Free Trial

Clarivate (CLVT) Competitors

Clarivate logo
$5.24 +0.11 (+2.14%)
(As of 11/22/2024 ET)

CLVT vs. RTO, ALLE, WPP, CART, ULS, MEDP, STN, GLOB, HQY, and BILI

Should you be buying Clarivate stock or one of its competitors? The main competitors of Clarivate include Rentokil Initial (RTO), Allegion (ALLE), WPP (WPP), Maplebear (CART), UL Solutions (ULS), Medpace (MEDP), Stantec (STN), Globant (GLOB), HealthEquity (HQY), and Bilibili (BILI). These companies are all part of the "business services" industry.

Clarivate vs.

Rentokil Initial (NYSE:RTO) and Clarivate (NYSE:CLVT) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Rentokil Initial has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Clarivate has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.

Rentokil Initial currently has a consensus price target of $29.00, suggesting a potential upside of 11.65%. Clarivate has a consensus price target of $7.25, suggesting a potential upside of 38.23%. Given Clarivate's higher probable upside, analysts plainly believe Clarivate is more favorable than Rentokil Initial.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rentokil Initial
0 Sell rating(s)
5 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.43
Clarivate
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Clarivate had 7 more articles in the media than Rentokil Initial. MarketBeat recorded 10 mentions for Clarivate and 3 mentions for Rentokil Initial. Clarivate's average media sentiment score of 0.47 beat Rentokil Initial's score of 0.39 indicating that Clarivate is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rentokil Initial
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Clarivate
4 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rentokil Initial has higher revenue and earnings than Clarivate.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rentokil Initial$6.68B1.96$473.93MN/AN/A
Clarivate$2.63B1.42-$911.20M-$1.99-2.64

9.9% of Rentokil Initial shares are owned by institutional investors. Comparatively, 85.7% of Clarivate shares are owned by institutional investors. 22.8% of Clarivate shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Rentokil Initial has a net margin of 0.00% compared to Clarivate's net margin of -50.00%. Clarivate's return on equity of 9.69% beat Rentokil Initial's return on equity.

Company Net Margins Return on Equity Return on Assets
Rentokil InitialN/A N/A N/A
Clarivate -50.00%9.69%3.97%

Clarivate received 45 more outperform votes than Rentokil Initial when rated by MarketBeat users. Likewise, 53.93% of users gave Clarivate an outperform vote while only 25.00% of users gave Rentokil Initial an outperform vote.

CompanyUnderperformOutperform
Rentokil InitialOutperform Votes
3
25.00%
Underperform Votes
9
75.00%
ClarivateOutperform Votes
48
53.93%
Underperform Votes
41
46.07%

Summary

Clarivate beats Rentokil Initial on 11 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLVT vs. The Competition

MetricClarivateData processing & preparation IndustryComputer SectorNYSE Exchange
Market Cap$3.73B$4.42B$23.84B$20.15B
Dividend YieldN/A3.00%2.76%3.50%
P/E Ratio-2.6434.79263.3344.29
Price / Sales1.425.943,241.8917.72
Price / Cash2.6731.3933.2521.28
Price / Book0.686.116.984.71
Net Income-$911.20M$42.17M$660.19M$985.54M
7 Day Performance21.13%6.11%3.67%3.73%
1 Month Performance-21.01%8.04%4.11%3.70%
1 Year Performance-27.85%14.68%20.93%27.73%

Clarivate Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLVT
Clarivate
2.7131 of 5 stars
$5.25
+2.1%
$7.25
+38.2%
-27.9%$3.73B$2.63B-2.6412,000Insider Trade
RTO
Rentokil Initial
1.0668 of 5 stars
$25.62
-0.3%
$29.00
+13.2%
-8.3%$12.94B$6.68B0.0062,900
ALLE
Allegion
4.3803 of 5 stars
$141.54
+1.5%
$144.60
+2.2%
+35.1%$12.30B$3.65B21.7412,400Positive News
WPP
WPP
0.5111 of 5 stars
$51.48
+0.1%
N/A+18.7%$11.71B$18.46B0.00114,732
CART
Maplebear
4.0139 of 5 stars
$43.21
+3.9%
$47.29
+9.4%
+72.5%$11.10B$3.04B29.003,380
ULS
UL Solutions
2.3277 of 5 stars
$53.12
+0.6%
$49.00
-7.8%
N/A$10.63B$2.68B0.0015,233
MEDP
Medpace
4.7474 of 5 stars
$341.87
+4.8%
$380.00
+11.2%
+22.0%$10.14B$2.07B29.945,900
STN
Stantec
2.9949 of 5 stars
$86.03
+2.3%
N/A+23.5%$9.81B$4.80B39.1028,000
GLOB
Globant
4.0868 of 5 stars
$222.37
+3.1%
$229.06
+3.0%
+7.7%$9.58B$2.35B58.0629,150Analyst Forecast
HQY
HealthEquity
3.7219 of 5 stars
$104.83
+1.8%
$107.23
+2.3%
+56.1%$9.15B$999.59M87.363,150Positive News
BILI
Bilibili
2.2792 of 5 stars
$18.88
-1.7%
$19.69
+4.3%
+30.1%$7.82B$3.19B-20.528,801Gap Down

Related Companies and Tools


This page (NYSE:CLVT) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners